Abstract:OBJECTIVE Povidone/Copovidone were used as the main osmopolymers instead of Poly (ethylene oxide) (PEO) to prepare nifedipine controlled-release tablets of new osmotic pump type. The pharmacokinetic properties of nifedipine controlled-release tablets after multiple doses in healthy volunteers were studied, and the relative bioavailability of the test preparation was calculated and the bioequivalence was evaluated. METHODS Twenty four male healthy volunteers were enrolled in a randomized two-way crossover design. 30 mg nifedipine was administered per day during consecutive 7 d. The drug concentration in blood was determined with LC-MS/MS method. The pharmacokinetic parameters, relative bioavailability and the bioequivalence were calculated by DAS program. RESULTS The main pharmacokinetic parameters after multiple doses of test preparation and reference preparation were as follows:T1/2β (9.0±2.2)h and (9.5±3.8)h; Tmax (8.1±7.4)h and (6.7±4.1)h; Cssmax (52.7±28.2)μg·L-1 and (44.5±22.6)μg·L-1; Cssmin (29.4±22.2)μg·L-1 and (28.7±15.8)μg·L-1; AUC0-60 (1 087.4±671.6)μg·L-1·h and (1 040.2±518.4)μg·L-1·h; AUC0-∞ (1 113.1±677.2)μg·L-1·h and (1 074.5±519.8)μg·L-1·h , AUCSS (809.1±454.0)μg·L-1·h and (713.9±382.2)μg·L-1·h. The average relative bioavailability of the test preparation versus the reference preparation was as follows: FAUCss (115.2±29.2)%, FAUC0-60 (103.4±30.2)% and FAUC0-∞ (102.2±29.7)%. DF was (77.84±52.09)% and (55.48±30.54)%. The 90% confidence interval of Cmax, AUC0-60, AUC0-∞ and AUCss after longarithmic transform was (100.9-126.0)%, (87.5-111.8)%, (86.8-110.3)% and (98.8-124.4)% respectively. There was no significant difference in Tmax after non-parameter rank sum test. No adverse reaction was observed during the trial. CONCLUSION The test preparation was bioequivalent to the reference preparation. Povidone/Copovidone could replace PEO used as the main functional excipient of osmotic pump type controlled-release preparations.

Research progress of techniques for preparation of nifedipine sustained and controlled release preparation

Preparation and in vitro evaluation of nifedipine controlled-release coated pellets

Research of Extended Release Nifedipine Tablets(I) release rate

Preparation Technique and Dissolution Rate of Nifedipine Sustained-release Hydrogels

Evaluation in vitro and in vivo of nifedipine controlled-release tablets

Preparation of Nifidipine Pulsatile Release Tablets

Pharmacokinetics and Bioequivalence Study of Nifedipine Controlled-release Tablets after Multiple Doses Administration in Healthy Volunteers

Preparation of Nitrendipine Sustained Release Tablets and Its Release in Vitro

Preparation of Nitrendipine Pulsatile Capsules Controlled by Erodible Plugs

Development and Evaluation of High Bioavailable Sustained-Release Nimodipine Tablets Prepared with Monolithic Osmotic Pump Technology

Investigation of the Release of Nifedipine from Sustained-Release Tablets Based on Compaction Properties of Hydroxypropyl Methylcellulose

Innovative dosage forms of nifedipine: assortment and development prospects

Raman Mapping-Based Reverse Engineering Facilitates Development of Sustained-Release Nifedipine Tablet

Nifedipine solid dispersion in microparticles of ammonio methacrylate copolymer and ethylcellulose binary blend for controlled drug delivery. Effect of drug loading on release kinetics

Studies on in Vivo and in Vitro Dissolution of Nitrendipine Delayed Release Tablets

A Liposomal Formulation for Improving Solubility and Oral Bioavailability of Nifedipine

Study on the Capsules of Nifedipine in the Form of the Solid Dispersion

Study on Pharmacokinetics and Bioavailability of Nimodipine Nanostructured Lipid Carrier in Rats

Study on the Preparation of nifedipine liposomes

A more rapid, sensitive, and specific HPLC-MS/MS method for nifedipine analysis in human plasma and application to a pharmacokinetic study.

Design and characterisation of an amorphous formulation of nifedipine for the treatment of autonomic dysreflexia